Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ipsen’s Cometriq approved for routine NHS use

Ipsen’s Cometriq approved for routine NHS use

16th February 2018

Ipsen's thyroid cancer treatment Cometriq has been cleared for routine use across the NHS.

The therapy has previously been available through the Cancer Drugs Fund, but the National Institute for Health and Care Excellence (NICE) said it had proved cost-effective and demonstrated its clinical value.

Cometriq has been recommended as a treatment for the relatively rare medullary thyroid cancer.

Ewan McDowall, general manager of Ipsen UK & Ireland, noted that patients with this disease typically have a poor prognosis and only a limited number of treatment options.

"We are therefore delighted that NICE has approved Cometriq for use via the NHS for eligible patients in England after previously being available via the Cancer Drugs Fund," he commented.

Mr McDowall added that any medicine with the potential to improve the life of a cancer patient should be treated as an "absolute priority", regardless of whether it is a common type of cancer or a rare type that affects a relatively small number of people.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.